S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
1907, 1929, 1998, 2007--and now 2023? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
1907, 1929, 1998, 2007--and now 2023? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
1907, 1929, 1998, 2007--and now 2023? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
1907, 1929, 1998, 2007--and now 2023? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
1907, 1929, 1998, 2007--and now 2023? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
1907, 1929, 1998, 2007--and now 2023? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
1907, 1929, 1998, 2007--and now 2023? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
1907, 1929, 1998, 2007--and now 2023? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
1907, 1929, 1998, 2007--and now 2023? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
1907, 1929, 1998, 2007--and now 2023? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
Tentative deal reached to end the Hollywood writers strike. No deal yet for actors
1907, 1929, 1998, 2007--and now 2023? (Ad)
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Canadian autoworkers ratify new labor agreement with Ford
1907, 1929, 1998, 2007--and now 2023? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:XERS

Xeris Biopharma (XERS) Stock Forecast, Price & News

$1.80
-0.05 (-2.70%)
(As of 09/22/2023 ET)
Compare
Today's Range
$1.78
$1.88
50-Day Range
$1.80
$2.69
52-Week Range
$0.97
$3.07
Volume
1.13 million shs
Average Volume
910,749 shs
Market Capitalization
$248.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.88

Xeris Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
170.8% Upside
$4.88 Price Target
Short Interest
Healthy
5.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$23,800 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.45) to ($0.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

283rd out of 963 stocks

Pharmaceutical Preparations Industry

118th out of 455 stocks


XERS stock logo

About Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

XERS Price History

XERS Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Why I Bought Google Stock Today
10 Best Fast Growing Penny Stocks to Buy Now
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Earnings Outlook For Xeris Biopharma Holdings
Xeris Ships One Millionth Gvoke® Unit
Xeris Pharmaceuticals (XERS) Gets a Buy from H.C. Wainwright
See More Headlines
Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

XERS Company Calendar

Last Earnings
8/08/2023
Today
9/24/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XERS
Fax
N/A
Employees
355
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.88
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+170.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-94,660,000.00
Pretax Margin
-54.29%

Debt

Sales & Book Value

Annual Sales
$134.07 million
Book Value
$0.33 per share

Miscellaneous

Free Float
132,046,000
Market Cap
$248.52 million
Optionable
Not Optionable
Beta
1.72

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Paul R. EdickMr. Paul R. Edick (Age 67)
    Chairman & CEO
    Comp: $1.12M
  • Mr. John P. Shannon (Age 61)
    Pres & COO
    Comp: $827.72k
  • Ms. Beth P. Hecht J.D. (Age 59)
    Chief Legal Officer & Corp. Sec.
    Comp: $638.31k
  • Mr. Steven M. Pieper (Age 46)
    Chief Financial Officer
  • Ms. Allison Wey
    Sr. VP of Investor Relations & Corp. Communications
  • Dr. Kenneth E. Johnson Pharm. D. (Age 60)
    Pharm.D., Sr. VP of Global Devel. & Medical Affairs
  • Mr. Kevin McCulloch
    Chief Commercial Officer













XERS Stock - Frequently Asked Questions

Should I buy or sell Xeris Biopharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" XERS shares.
View XERS analyst ratings
or view top-rated stocks.

What is Xeris Biopharma's stock price forecast for 2023?

4 Wall Street research analysts have issued twelve-month target prices for Xeris Biopharma's shares. Their XERS share price forecasts range from $4.00 to $6.00. On average, they expect the company's share price to reach $4.88 in the next twelve months. This suggests a possible upside of 170.8% from the stock's current price.
View analysts price targets for XERS
or view top-rated stocks among Wall Street analysts.

How have XERS shares performed in 2023?

Xeris Biopharma's stock was trading at $1.33 at the beginning of 2023. Since then, XERS stock has increased by 35.3% and is now trading at $1.80.
View the best growth stocks for 2023 here
.

When is Xeris Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our XERS earnings forecast
.

How were Xeris Biopharma's earnings last quarter?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) issued its earnings results on Tuesday, August, 8th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The firm earned $38.01 million during the quarter, compared to analysts' expectations of $34.84 million. Xeris Biopharma had a negative trailing twelve-month return on equity of 191.02% and a negative net margin of 53.28%.

What ETF holds Xeris Biopharma's stock ?

iShares Neuroscience and Healthcare ETF holds 15,969 shares of XERS stock, representing 0.79% of its portfolio.

What guidance has Xeris Biopharma issued on next quarter's earnings?

Xeris Biopharma updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $145.00 million-$165.00 million, compared to the consensus revenue estimate of $149.35 million.

What other stocks do shareholders of Xeris Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI).

When did Xeris Biopharma IPO?

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Xeris Biopharma's stock symbol?

Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS."

Who are Xeris Biopharma's major shareholders?

Xeris Biopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.89%), Caxton Corp (4.09%), Stonepine Capital Management LLC (3.98%), Geode Capital Management LLC (1.98%), State Street Corp (1.84%) and Northern Trust Corp (0.85%). Insiders that own company stock include Paul R Edick and Steven Prestrelski.
View institutional ownership trends
.

How do I buy shares of Xeris Biopharma?

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xeris Biopharma's stock price today?

One share of XERS stock can currently be purchased for approximately $1.80.

How much money does Xeris Biopharma make?

Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $248.52 million and generates $134.07 million in revenue each year. The company earns $-94,660,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Xeris Biopharma have?

The company employs 355 workers across the globe.

How can I contact Xeris Biopharma?

Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for the company is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com.

This page (NASDAQ:XERS) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -